Questionnaire

In terms of comorbidity and risk factor management in patients with AF, the 2024 ESC guidelines place emphasis on the presence of:

In terms of avoiding stroke and thromboembolism in the patient with AF, the 2024 ESC guidelines recommend first-line anticoagulation using:

The 2024 ESC guidelines for the management of AF recommend that evaluation and dynamic reassessment take place:

The increasing prevalence of AF is primarily a consequence of an ageing population, and is also due to the advent and broader use of new technologies which identify AF more accurately than previously able.

An alert from a wearable device indicating the presence of a dysrhythmia is diagnostic of AF.

Compared with men who have AF, real-world evidence indicates that the presence of AF symptoms and the impact on quality of life in women is

Symptoms of AF include:

Adverse outcomes of AF include:

Asymptomatic patients are equally at risk of stroke compared to symptomatic patients with typical AF palpitations and face a similar comorbidity
burden; however, symptoms do impact on a patient’s quality of life.

When calculating risk of stroke in the patient with AF, an attribute that is no longer considered to be a risk factor in the simplified 2024 CHA2
DS2-VA scoring system is:

Compared with warfarin for the prevention of stroke in patients with AF, DOACs have:

Compared with warfarin for the prevention of stroke in patients with AF, DOACs can be used:

The DOAC that is most closely associated with haemorrhagic events is:

The CHEST guideline-recommended treatment-phase antithrombotic therapy for patients with DVT of the leg or PE prefers:

For patients requiring extended-phase anticoagulation, guidelines recommend reduced-dose DOAC over: